Skip to content

Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients

Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04984941
Enrollment
100
Registered
2021-08-02
Start date
2013-03-01
Completion date
2014-10-01
Last updated
2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis, Asthma, Atopic Dermatitis, Conjunctivitis

Keywords

House dust mite, Der p 1, Der p 2, China

Brief summary

One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics. Serum IgE reactivity toDermatophagoides pteronyssinus (Dp) extract, Der p 1, Der p 2 and Der p 10 was measured by ImmunoCAP.

Detailed description

Background: The role of specific IgE (sIgE) against Der p 1and Der p 2 in Chinese patients with house dust mite (HDM)allergy has not yet been well investigated.Methods: One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics. Serum IgE reactivity toDermatophagoides pteronyssinus (Dp) extract, Der p 1, Der p 2 and Der p 10 was measured by ImmunoCAP.

Interventions

None listed

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
3 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* HDM-allergic patients reporting allergic rhinitis, conjunctivitis, asthma and/or atopic dermatitis and who had never undergone immunotherapy, were enrolled if they were sensitized to Dp as judged by ImmunoCAP ( ≥ 1 kU/l) and/or skin reaction index (SRI)by skin-prick test (SPT, a wheal diameter ≥ 0.5 mm).

Exclusion criteria

* Patients who refused to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Demographic Characteristics1 yearDescribe the patient's basic information in detail, including age, gender, family history, etc
Der p 1 Serum IgE1 yearPrevalence of Der p 1 Serum IgE in HDM-Allergic Patients
Der p 2 Serum IgE1 yearPrevalence of Der p 2 Serum IgE in HDM-Allergic Patients
Dp, Der p 1 and Der p 21 yearRelationship between Serum IgE Levels of Dp, Der p 1 and Der p 2
Factors associated with specific IgE against Der p 11 yearStudy the patient's basic information and identify factors that are clearly associated with specific IgE against Der p 1
Factors associated with specific IgE against Der p 21 yearStudy the patient's basic information and identify factors that are clearly associated with specific IgE against Der p 2
the Number of Affected Organs1 yearAssociation of Specific IgE Titers with the Number of Affected Organs

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026